Daniel McGowan, MD
Interventional Cardiology · Kearney, NENPI 1780667931
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 514 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Abbott at 31.4% of the total. Reporting peaked in 2022 at $2,336 and has fallen 69.7% since, to $708 in 2025.
Across 514 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- AstraZeneca$1K
- Pfizer$984
- Impulse Dynamics (USA) Inc.$731
- Johnson & Johnson$670
- Novartis$505
- plus $2K from 18 others
What the payments were for
- Consulting fees$471%
- Food & beverage$8,64699%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 194 | $2,740 |
| AstraZeneca | 53 | $1,063 |
| Pfizer | 77 | $984 |
| Impulse Dynamics (USA) Inc. | 12 | $731 |
| Johnson & Johnson | 40 | $670 |
| Novartis | 34 | $505 |
| Amgen | 24 | $408 |
| Merck | 25 | $357 |
| Boehringer Ingelheim | 15 | $252 |
| Sanofi-aventis U.S. LLC | 9 | $150 |
| Inspire Medical Systems, Inc. | 1 | $150 |
| Actelion Pharmaceuticals US, Inc. | 6 | $147 |
| Corcym Inc | 1 | $110 |
| Boston Scientific | 5 | $104 |
| Lundbeck LLC | 4 | $73 |
| Arbor Pharmaceuticals, Inc. | 4 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Itamar Medical Inc | 1 | $47 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Abiomed | 1 | $28 |
| Gilead | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $19 |
| AbbVie | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$750
- Inspire Upper Airway Stimulation System$150
- AVEIR$116
- MEMO 4D$110
How this compares
$8,716 in reported general payments places this provider in the 55th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 1,110 | $828,651 |
| EliquisApixaban | 835 | $532,828 |
| EntrestoSacubitril/Valsartan | 242 | $167,819 |
| Repatha SureclickEvolocumab | 189 | $125,886 |
| FarxigaDapagliflozin Propanediol | 176 | $110,559 |
| MultaqDronedarone Hcl | 71 | $67,628 |
| Praluent PenAlirocumab | 86 | $44,287 |
| SotalolSotalol Hcl | 1,747 | $25,583 |
| Repatha SyringeEvolocumab | 50 | $25,150 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 130 | $22,109 |
| JardianceEmpagliflozin | 21 | $19,532 |
| BrilintaTicagrelor | 33 | $19,006 |
| Losartan Potassium | 1,373 | $17,573 |
| Propafenone Hcl | 461 | $11,334 |
| LivaloPitavastatin Calcium | 24 | $9,463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $670 | $828,6511,110 claims |
| PfizerEliquis | $984 | $532,828835 claims |
| NovartisEntresto | $505 | $167,819242 claims |
| AstraZenecaFarxiga, Brilinta | $1,063 | $129,566209 claims |
| Sanofi-aventis U.S. LLCMultaq | $150 | $67,62871 claims |
| Boehringer IngelheimJardiance, Pradaxa | $252 | $27,59770 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in Kearney
- James HallKearney$36K
- John WatersKearney$4K
- Vinayak NagarajaKearney$4K
- Sean DenneyKearney$1K
- Panayotis Alain EfstratiouKearney$722
- Brock CookmanLincoln$782K
- Himanshu AgarwalOmaha$541K
- Matthew JohnsonLincoln$162K
- Poonam VelagapudiOmaha$142K
- Steven MartinLincoln$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.